Biotech Values

[mcbio]

White lie from ONTY’s CEO:

www.reuters.com/article/2012/01/11/us-healthcare-oncothyreon-idUSTRE80A24F20120111
Quote:
--------------------------------------------------------------------------------
“We would be perfectly content if the decision is to continue the [Stimuvax] trial to its end,” Kirkman said.
--------------------------------------------------------------------------------

In truth, he will be disappointed if this should happen. Failure of Stimuvax to hit the success threshold in the second interim analysis would further narrow the window for the best-case scenario in which Stimuvax shows extraordinarily strong efficacy.

Yeah, that's a bit of a silly statement.